HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder - PubMed (original) (raw)
HER2/neu overexpression in the development of muscle-invasive transitional cell carcinoma of the bladder
Z Latif et al. Br J Cancer. 2003.
Abstract
The mortality from transitional cell carcinoma (TCC) of the urinary bladder increases significantly with the progression of superficial or locally invasive disease (pTa/pT1) to detrusor muscle-invasive disease (pT2+). The most common prognostic markers in clinical use are tumour stage and grade, which are subject to considerable intra- and interobserver variation. Polysomy 17 and HER2/neu gene amplification and protein overexpression have been associated with more advanced disease. Standardised techniques of fluorescence in situ hybridisation and immunohistochemistry, which are currently applied to other cancers with a view to offering anti-HER2/neu therapies, were applied to tumour pairs comprising pre- and postinvasive disease from 25 patients undergoing treatment for bladder cancer. In the preinvasive tumours, increased HER2/neu copy number was observed in 76% of cases and increased chromosome 17 copy number in 88% of cases, and in the postinvasive group these values were 92 and 96%, respectively (not significantly different P=0.09 and 0.07, respectively). HER2 gene amplification rates were 8% in both groups. Protein overexpression rates were 76 and 52%, respectively, in the pre- and postinvasive groups (P=0.06). These results suggest that HER2/neu abnormalities occur prior to and persist with the onset of muscle-invasive disease. Gene amplification is uncommon and other molecular mechanisms must account for the high rates of protein overexpression. Anti-HER2/neu therapy might be of use in the treatment of TCC.
Similar articles
- HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. Latif Z, et al. Eur J Cancer. 2004 Jan;40(1):56-63. doi: 10.1016/j.ejca.2003.08.027. Eur J Cancer. 2004. PMID: 14687790 - Role of polysomy 17 in transitional cell carcinoma of the bladder: immunohistochemical study of HER2/neu expression and fish analysis of c-erbB-2 gene and chromosome 17.
Simonetti S, Russo R, Ciancia G, Altieri V, De Rosa G, Insabato L. Simonetti S, et al. Int J Surg Pathol. 2009 Jun;17(3):198-205. doi: 10.1177/1066896909333415. Int J Surg Pathol. 2009. PMID: 19443884 - Prognostic value of HER2 status in bladder transitional cell carcinoma revealed by both IHC and BDISH techniques.
Nedjadi T, Al-Maghrabi J, Assidi M, Dallol A, Al-Kattabi H, Chaudhary A, Al-Sayyad A, Al-Ammari A, Abuzenadah A, Buhmeida A, Al-Qahtani M. Nedjadi T, et al. BMC Cancer. 2016 Aug 19;16:653. doi: 10.1186/s12885-016-2703-5. BMC Cancer. 2016. PMID: 27539085 Free PMC article. - HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder.
Coogan CL, Estrada CR, Kapur S, Bloom KJ. Coogan CL, et al. Urology. 2004 Apr;63(4):786-90. doi: 10.1016/j.urology.2003.10.040. Urology. 2004. PMID: 15072912 - HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role.
Sanguedolce F, Zanelli M, Palicelli A, Bisagni A, Zizzo M, Ascani S, Pedicillo MC, Cormio A, Falagario UG, Carrieri G, Cormio L. Sanguedolce F, et al. Int J Mol Sci. 2023 Feb 13;24(4):3720. doi: 10.3390/ijms24043720. Int J Mol Sci. 2023. PMID: 36835131 Free PMC article. Review.
Cited by
- Assessment of the expression pattern of HER2 and its correlation with HER2-targeting antibody-drug conjugate therapy in urothelial cancer.
Lei H, Ling Y, Yuan P, Yan X, Wang L, Shi Y, Yao X, Luo H, Shi B, Liu J, He Z, Yu G, Han W, Hu C, Chi Z, Cui C, Si L, Fang J, Guo J, Sheng X, Zhou A, Ying J. Lei H, et al. J Natl Cancer Cent. 2023 Mar 1;3(2):121-128. doi: 10.1016/j.jncc.2023.02.003. eCollection 2023 Jun. J Natl Cancer Cent. 2023. PMID: 39035731 Free PMC article. - HER2 positivity predicts BCG unresponsiveness and adaptive immune cell exhaustion in EORTC risk-stratified cohort of bladder cancer.
Nam W, Chae HK, Jung Y, Kang H, Park M, Choi A, Park JY, Eom DW, Kim SJ. Nam W, et al. Front Immunol. 2023 Dec 8;14:1301510. doi: 10.3389/fimmu.2023.1301510. eCollection 2023. Front Immunol. 2023. PMID: 38143745 Free PMC article. - Efficacy of a HER2-Targeted Thorium-227 Conjugate in a HER2-Positive Breast Cancer Bone Metastasis Model.
Karlsson J, Hagemann UB, Cruciani V, Schatz CA, Grant D, Ellingsen C, Kristian A, Katoozi S, Mihaylova D, Uran SR, Suominen M, Bjerke RM, Ryan OB, Cuthbertson A. Karlsson J, et al. Cancers (Basel). 2023 Jun 29;15(13):3419. doi: 10.3390/cancers15133419. Cancers (Basel). 2023. PMID: 37444529 Free PMC article. - Targeted Therapy for Locally Advanced or Metastatic Urothelial Cancer (mUC): Therapeutic Potential of Sacituzumab Govitecan.
Fontes MS, Vargas Pivato de Almeida D, Cavalin C, Tagawa ST. Fontes MS, et al. Onco Targets Ther. 2022 Dec 21;15:1531-1542. doi: 10.2147/OTT.S339348. eCollection 2022. Onco Targets Ther. 2022. PMID: 36575731 Free PMC article. Review. - HER2 expression in urothelial carcinoma, a systematic literature review.
Scherrer E, Kang A, Bloudek LM, Koshkin VS. Scherrer E, et al. Front Oncol. 2022 Oct 21;12:1011885. doi: 10.3389/fonc.2022.1011885. eCollection 2022. Front Oncol. 2022. PMID: 36338710 Free PMC article.
References
- Bae CD, Juhnn YS, Park JB (2001) Post-transcriptional control of c-erb B2 overexpression in stomach cancer cells. Exp Mol Med 37(1): 15–19 - PubMed
- Bartlett JMS, Adie L, Watters AD, Going JJ, Grigor KM (1999) Chromosomal aberrations in transitional cell carcinoma that are predictive of disease outcome are independent of polyploidy. Br J Urol Int 84(7): 775–779 - PubMed
- Bartlett JM, Goint JJ, Mallon EA, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG (2001) Evaluating her 2 amplification and overexpression in breast cancer. J path 195(4): 422–428 - PubMed
- Baselga J (2001) Clinical trials of Herceptin. Eur J Cancer 37: s18–s24 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous